Thanks for sharing YD
Tend to agree with you Mac which begs the question- what would be the right price and for what?
Total business assets buy-out or licensing options?
Merck is obviously in pole position for either above options, but they would want exclusively and therefore would think licensing not an option.
Merck has plenty of cash in the kitty but could be playing games especially with current biotech market caps being so low.
- Forums
- ASX - By Stock
- Overnight Market report
Thanks for sharing YDTend to agree with you Mac which begs the...
-
- There are more pages in this discussion • 1,385 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
40.0¢ |
Change
-0.005(1.23%) |
Mkt cap ! $581.0M |
Open | High | Low | Value | Volume |
40.5¢ | 40.5¢ | 39.5¢ | $998.2K | 2.495M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 7607 | 39.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.0¢ | 36888 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 7607 | 0.395 |
6 | 202444 | 0.390 |
4 | 118064 | 0.385 |
6 | 53762 | 0.380 |
1 | 8500 | 0.375 |
Price($) | Vol. | No. |
---|---|---|
0.400 | 36888 | 3 |
0.405 | 151772 | 3 |
0.410 | 218559 | 6 |
0.415 | 230895 | 10 |
0.420 | 469144 | 7 |
Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |